“ALL 硬”- K药强势“ALL-IN”消化道肿瘤( 五 )

本文插图

KEYNOTE-524：2020年ASCO发布更新数据， ORR 46%（mRECISTper IIR）， DCR 88%（mRECIST perIIR）[14]

本文插图

KEYNOTE-524: 2020年ASCO发布随访更新数据， mOS 22.0个月[14]LEAP-002是一项全球多中心（172），随机、双盲对照的III期临床研究，对比“可乐”组合和仑伐替尼一线治疗晚期肝细胞癌的疗效和安全性；研究自2018年年底启动，计划入组750例患者[9] 。
LEAP-002能否接过KEYNOTE-524火炬，改写肝癌一线治疗方案，改变临床实践， 2021年有望见分晓。
参考资料：
[1] Thierry Andre, First-line therapy of pembrolizumab versus standardof care （SOC） in microsatellite instability-high/mismatch repairdeficient metastatic colorectal cancer: The phase III, KEYNOTE-177 study. ASCO 2020, LBA4
[2] Thierry Andre et al., Final overall survival for the phase IIIKN177 study: Pembrolizumab versus chemotherapy in microsatelliteinstability-high/mismatch repair deficient （MSI-H/dMMR） metastatic colorectal cancer （mCRC）. 2021 ASCO Abstract 3500
[3] Ken Kato et al., Pembrolizumab Plus Chemotherapy VersusChemotherapy as First-Line Therapy in Patients with Advanced Esophageal Cancer:The Phase 3 KEYNOTE-590 Study, ESMO 2020, LBA 8
[4] Zhigang Li et al., First-line pembrolizumab plus chemotherapyversus chemotherapy in patients with advanced esophageal cancer: Chinesesubgroup analysis of KEYNOTE-590. 2021 ASCO Abstract 4049
[5] Yelena Y. Janjigian, et al., Pembrolizumab plus trastuzumab andchemotherapy for HER2+ metastatic gastric or gastroesophageal junction （G/GEJ） cancer: Initial findings of the global phase 3 KEYNOTE-811 study.2021 ASCO Abstract 4013
[6] J.Tabernero et al., Pembrolizumab With or Without ChemotherapyVersus Chemotherapy in Advanced G/GEJ Adenocarcinoma: The Phase 3, KEYNOTE-062Study, 2019 ASCO LBA4007
[7] Kohei Shitara et al., Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer The KEYNOTE-062Phase 3 Randomized Clinical Trial, JAMAOncol. doi:10.1001/jamaoncol.2020.3370
Published online September 3, 2020.
[8] H. Satake et al., Pembrolizumab Versus Standard-of-CareChemotherapy in Patients With Advanced Gastric or Gastroesophageal JunctionAdenocarcinoma: Asian Subgroup Analysis of KEYNOTE-062, 2020 ASCO PosterDiscussion, Abstract 4523
[9] www.clinicaltrials.gov
[10] Richard S. Finn et al., Pembrolizumab （pembro） versus placebo （pbo） in patients （pts） with advanced hepatocellular carcinoma （aHCC） previously treated with sorafenib: Updated data from the randomized,phase 3 KEYNOTE-240 study. 2021 ASCO Abstract 4072
[11] Richard Finn et al., Results of KEYNOTE-240: Phase 3 Study ofPembrolizumab vs Best Supportive Care for Second-Line Therapy in AdvancedHeptocellular Carcinoma, 2019 ASCO, Abstract 4004, Oral Abstract Session